Yahoo Finance14d
Sarepta rebuilds drug pipeline with Arrowhead deal
Arrowhead will hand over responsibility for the preclinical ... genetic diseases,” said Louise Rodino-Klapac, Sarepta’s chief ...
Hosted on MSN18d
Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
This achievement validates its scientific approach and positions the company for future growth and success. Baron Opportunity Fund made the following comment about Arrowhead Pharmaceuticals ...
Business Insider23d
Arrowhead announces new PALISADE study results
Arrowhead (ARWR) announced new results from the Phase 3 PALISADE ... These data were presented in two oral presentations at the American Heart Association Scientific Sessions and PALISADE data was ...
Business Wire1mon
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial ...
Arrowhead hosted a launch event at its Pasadena ... the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting ...
Muscular Dystrophy News7d
Sarepta to develop Arrowhead’s muscular dystrophy treatments
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
Yahoo Finance23d
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
November 18, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA ...